Integra LifeSciences (IART) Tops Q1 EPS by 6c

Integra LifeSciences (NASDAQ: IART) reported Q1 EPS of $0.74, $0.06 better than the analyst estimate of $0.68. Revenue for the quarter came in at $376.6 million versus the consensus estimate of $362.04 million.

GUIDANCE:

Integra LifeSciences sees FY2022 EPS of $3.27-$3.35, versus the consensus of $3.31.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• Argus Upgrades Integra LifeSciences (IART) to Buy, 'Valuations are still low'
• Citi sees this stock as primary lithium demand beneficiary, upgrades to Buy
• Pfizer reaffirms 2026 guidance after CFO transition news